Mizuho cuts LeonaBio stock price target on financing concerns
Mizuho reduced its price target for LeonaBio (LONA) to $12 from $13, citing financing concerns after warrants expired unexercised. The stock is down 29% this week. Mizuho maintains an Outperform rating, noting progress in the ELAINE-3 study and a supportive investor base. LeonaBio reported Q3 2026 results, confirming trial enrollment completion by year-end 2026. Other analysts also adjusted price targets.
How this was made
The 30-second read
Why it matters
Analyst target reductions reflect perceived funding risk, which could depress the share price in the near term.
Market read
The downgrade and financing overhang are new information that may influence short‑term trading decisions on LONA.
What to watch
Strong cash position and a favorable current ratio may mitigate short‑term risk if new capital is secured.
Background
LeonaBio reported Q3 2026 results, highlighted progress on its Phase 3 ELAINE‑3 trial, and faced a $146 M warrant expiration that created financing concerns.
Ticker impact
Mizuho lowered its price target on LeonaBio to $12, citing financing overhang and recent Q3 results.
downward pressure as investors price in the reduced target and cash‑burn risk
The target cut and mention of unexercised warrants signal near‑term funding risk, likely prompting sell‑side activity.
Market effects
Biotech sector may see heightened scrutiny on cash‑burn and financing structures.
US small‑cap biotech investors could adjust exposure.
Limited to investors tracking early‑stage oncology pipelines.
Counterpoint
Despite the target cut, the stock remains far below its 52‑week high, offering a potential upside if financing improves.
Key entities
- companyLeonaBio
NASDAQ‑listed biotech developing lasofoxifene for advanced breast cancer.
- analystMizuho
Equity research firm that lowered its price target on LeonaBio.


